Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan. [electronic resource]
Producer: 20200630Description: 80-85 p. digitalISSN:- 1941-837X
- Adalimumab -- economics
- Biological Products -- economics
- Clinical Trials, Phase III as Topic
- Cost-Benefit Analysis
- Crohn Disease -- drug therapy
- Gastrointestinal Agents -- economics
- Humans
- Infliximab -- economics
- Japan
- Network Meta-Analysis
- Randomized Controlled Trials as Topic
- Remission Induction
- Severity of Illness Index
- Ustekinumab -- economics
No physical items for this record
Publication Type: Journal Article; Meta-Analysis
There are no comments on this title.
Log in to your account to post a comment.